A methodologic problem and a conceptual issue related to the new 2022 antineutrophil cytoplasmic antibody-related vasculitis criteria sets: comment on criteria sets approved by the American College of Rheumatology Board of Directors and the European Alliance of Associations for Rheumatology Executive Committee.